BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 23898484)

  • 1. Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients.
    Kumar S; Keerthana R; Pazhanimuthu A; Perumal P
    Indian J Biochem Biophys; 2013 Jun; 50(3):210-4. PubMed ID: 23898484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased serum miR-181a is a potential new tool for breast cancer screening.
    Guo LJ; Zhang QY
    Int J Mol Med; 2012 Sep; 30(3):680-6. PubMed ID: 22692639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls.
    Hu Z; Dong J; Wang LE; Ma H; Liu J; Zhao Y; Tang J; Chen X; Dai J; Wei Q; Zhang C; Shen H
    Carcinogenesis; 2012 Apr; 33(4):828-34. PubMed ID: 22298638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of serum genome-wide microRNAs for breast cancer detection.
    Wu Q; Wang C; Lu Z; Guo L; Ge Q
    Clin Chim Acta; 2012 Jul; 413(13-14):1058-65. PubMed ID: 22387599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. U6 is not a suitable endogenous control for the quantification of circulating microRNAs.
    Xiang M; Zeng Y; Yang R; Xu H; Chen Z; Zhong J; Xie H; Xu Y; Zeng X
    Biochem Biophys Res Commun; 2014 Nov; 454(1):210-4. PubMed ID: 25450382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating microRNAs in plasma of patients with gastric cancers.
    Tsujiura M; Ichikawa D; Komatsu S; Shiozaki A; Takeshita H; Kosuga T; Konishi H; Morimura R; Deguchi K; Fujiwara H; Okamoto K; Otsuji E
    Br J Cancer; 2010 Mar; 102(7):1174-9. PubMed ID: 20234369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
    Kim SY; Jeon TY; Choi CI; Kim DH; Kim DH; Kim GH; Ryu DY; Lee BE; Kim HH
    J Mol Diagn; 2013 Sep; 15(5):661-9. PubMed ID: 23806809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer.
    Zhang L; Xu Y; Jin X; Wang Z; Wu Y; Zhao D; Chen G; Li D; Wang X; Cao H; Xie Y; Liang Z
    Breast Cancer Res Treat; 2015 Nov; 154(2):423-34. PubMed ID: 26476723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum miR-146a and miR-223 as potential new biomarkers for sepsis.
    Wang JF; Yu ML; Yu G; Bian JJ; Deng XM; Wan XJ; Zhu KM
    Biochem Biophys Res Commun; 2010 Mar; 394(1):184-8. PubMed ID: 20188071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer.
    Tang D; Shen Y; Wang M; Yang R; Wang Z; Sui A; Jiao W; Wang Y
    Eur J Cancer Prev; 2013 Nov; 22(6):540-8. PubMed ID: 23462458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
    Madhavan D; Zucknick M; Wallwiener M; Cuk K; Modugno C; Scharpff M; Schott S; Heil J; Turchinovich A; Yang R; Benner A; Riethdorf S; Trumpp A; Sohn C; Pantel K; Schneeweiss A; Burwinkel B
    Clin Cancer Res; 2012 Nov; 18(21):5972-82. PubMed ID: 22952344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum miR-103 as a potential diagnostic biomarker for breast cancer].
    Wang X; Wu X; Yan L; Shao J
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 May; 32(5):631-4. PubMed ID: 22588912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer.
    Heneghan HM; Miller N; Lowery AJ; Sweeney KJ; Newell J; Kerin MJ
    Ann Surg; 2010 Mar; 251(3):499-505. PubMed ID: 20134314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating miR-34a levels are reduced in colorectal cancer.
    Nugent M; Miller N; Kerin MJ
    J Surg Oncol; 2012 Dec; 106(8):947-52. PubMed ID: 22648208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus.
    Wang H; Peng W; Ouyang X; Li W; Dai Y
    Transl Res; 2012 Sep; 160(3):198-206. PubMed ID: 22683424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma miR-21: a potential diagnostic marker of colorectal cancer.
    Kanaan Z; Rai SN; Eichenberger MR; Roberts H; Keskey B; Pan J; Galandiuk S
    Ann Surg; 2012 Sep; 256(3):544-51. PubMed ID: 22868372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.
    Markou A; Zavridou M; Sourvinou I; Yousef G; Kounelis S; Malamos N; Georgoulias V; Lianidou E
    Clin Chem; 2016 Jul; 62(7):1002-11. PubMed ID: 27197674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High degree of correlation between whole blood and PBMC expression levels of miR-155 and miR-146a in healthy controls and rheumatoid arthritis patients.
    Mookherjee N; El-Gabalawy HS
    J Immunol Methods; 2013 Dec; 400-401():106-10. PubMed ID: 24120842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer.
    Lu YC; Chang JT; Huang YC; Huang CC; Chen WH; Lee LY; Huang BS; Chen YJ; Li HF; Cheng AJ
    Clin Biochem; 2015 Feb; 48(3):115-21. PubMed ID: 25485932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer.
    Li C; Li JF; Cai Q; Qiu QQ; Yan M; Liu BY; Zhu ZG
    J Surg Oncol; 2013 Aug; 108(2):89-92. PubMed ID: 23733518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.